Compositions and methods related to mammalian Maf-A

• US 20050118148A1
• Filed: 12/19/2003
• Published: 06/02/2005
• Est. Priority Date: 12/20/2002
• Status: Abandoned Application

• Current Assignee: Vanderbilt University
• Original Assignee: Vanderbilt University
• Inventors: Zhao, Li, Matsuoka, Taka-aki, Stein, Roland
• Application Number:
  US10/741,158
• Publication Number:
  US 20050118148A1
• Time in Patent Office: Days
• US Class Current: 424/93.210
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: C07K 14/4702 Regulators; Modulating activity
• CPC Class Codes: C12N 2501/60 Transcription factors
• CPC Class Codes: C12N 2510/00 Genetically modified cells
• CPC Class Codes: C12N 5/0676 Pancreatic cells

Abstract

Various embodiments of the invention include methods of generating a β-like cell comprising providing an expression cassette comprising a nucleic acid sequence encoding MafA under the control of a heterologous promoter and transferring the expression cassette into a non-insulin producing cell, wherein the expression of the MafA in the cell converts the cell into a β-like cell.

Claims

1. A method of generating a β

-like cell comprising;

a) providing an expression cassette comprising a nucleic acid sequence encoding MafA under the control of a heterologous promoter; and

b) transferring the expression cassette into a non-insulin producing cell, wherein the expression of the MafA in the cell converts the cell into a β

-like cell.

2. The method of claim 1, wherein the cell is further defined as a progenitor cell.

3. The method of claim 2, wherein the progenitor cell is further defined as a pancreatic progenitor cell.

4. The method of claim 1, wherein the cell is immortalized.

5. The method of claim 4, wherein the immortalized cell is susceptible to a cell kill agent.

6. The method of claim 5, wherein the immortalized cell further comprises a heterologous nucleic acid segment encoding a polypeptide that renders the cell susceptible to the cell kill agent.

7. The method of claim 6, wherein a nucleic acid segment encodes the cell kill agent and is under the control of an inducible promoter.

8. The method of claim 1, wherein the expression cassette is comprised in a non-viral vector.

9. The method of claim 8, wherein the non-viral vector is further defined as a plasmid.

10. The method of claim 1, wherein the expression cassette is comprised in a viral vector.

11. The method of claim 10, wherein the viral vector is an adenovirus, a retrovirus, a herpes-simplex virus, a vaccinia virus or an adeno-associated virus.

12. The method of claim 8, wherein the expression cassette is transferred into the cell by a non-viral delivery system.

13. The method of claim 12, wherein the non-viral delivery system is further defined as calcium phosphate precipitation, DEAE-dextran, electroporation, direct microinjection, DNA-loaded liposomes, cell sonification, gene bombardment using high velocity microprojectiles or receptor-mediated transfection.

14. The method of claim 1, wherein the promoter is further defined as an inducible promoter.

15. The method of claim 14, wherein the promoter promoter is a metallothonine promoter.

16. The method of claim 14, wherein the promoter is an inducible promoter.

17. The method of claim 16, further comprising providing to the cell an inducer of the promoter.

18. A method of generating a β

-like cell comprising;

a) providing a MafA protein comprising a nuclear localization signal; and

b) contacting a cell with a sufficient amount of the MafA protein;

wherein contacting the cell with a sufficient amount of the MafA protein converts the cell into a β

-like cell.

19. The method of claim 18, wherein the cell is further defined as a progenitor cell.

20. The method of claim 19, wherein the progenitor cell is further defined as a pancreatic progenitor cell.

21. The method of claim 18, wherein the cell is immortalized.

22. The method of claim 21, wherein the immortalized cell is susceptible to a cell kill agent.

23. The method of claim 22, wherein the immortalized cell further comprises a heterologous nucleic acid segment encoding a polypeptide that renders the cell susceptible to the cell kill agent.

24. The method of claim 22, wherein a nucleic acid segment encodes the cell kill agent and is under the control of an inducible promoter.

25. An implantable device for treating diabetes in a subject comprising:

a) a receptacle suitable for holding live cells; and

b) a cell-impermeable membrane operably fixed to the receptacle so as to confine the cells within the receptacle, wherein the membrane is permeable to insulin, regulatory signals that regulate the production of insulin and other factors necessary for the survival of the cells.

26. The device of claim 25, wherein the device is suitable for placement in a human body.

27. The device of claim 25, wherein the regulatory signal is glucose.

28. The device of claim 25, wherein the factors comprise nutrients.

29. A method of providing regulated insulin production to a subject comprising providing an effective amount of a composition comprising a β

-like cell to a subject, wherein the β

-like cell comprises an expression cassette comprising a nucleic acid sequence encoding MafA under the control of a heterologous promoter.

30. The method of claim 29, wherein the subject is a human.

31. The method of claim 29, wherein the heterologous promoter is an inducible promoter.

32. The method of claim 29, wherein the expression cassette is maintained in an episomal form or integrated into the cell genome.

33. A method of treating diabetes in a subject comprising providing an effective amount of a composition comprising a β

-like cell to a subject, wherein the β

-like cell comprises an expression cassette comprising a nucleic acid sequence encoding MafA under the control of a heterologous promoter.

34. The method of claim 33, wherein the subject is a human.

35. The method of claim 33, wherein the diabetes is Type I diabetes.

36. The method of claim 33, wherein the diabetes is Type II diabetes.

37. The method of claim 33, wherein the heterologous promoter is an inducible promoter.

38. The method of claim 33, wherein the expression cassette is maintained in an episomal form or integrated into the cell genome.

39. A composition comprising a β

-like cell, wherein the β

-like cell comprises an expression cassette comprising a nucleic acid sequence encoding MafA under the control of a heterologous promoter.

40. The method of claim 39, wherein the heterologous promoter is an inducible promoter.

41. The method of claim 39, wherein the expression cassette is maintained in an episomal form or integrated into the cell genome.